4 sources checked · 2 source groups included · 58m ago
Still Watching
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
Quartz and Market Watch describe the same event in different terms.
1 Left3 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of July 31, 2026 at 1:54 PM, this is how Optics News reads the wording differences in this story.
What happenedThe experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
The headline splitThe left frames it as "Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial". The center frames it as "Novo Nordisk shares drop 10% after cardiovascular drug trial disappoints".
Match confidenceMedium confidence. 4 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
4 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
56/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftNovo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
Quartz · Center-left · News report
CenterNovo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
CNBC · Center · News report
Right / center-rightNo matching source in this bucket yet.
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients